The use of Quality-Adjusted Life Years in cost-effectiveness analyses in palliative care: Mapping the debate through an integrative review

Palliative Medicine

Volumn 31, Issue 4, 2017, Pages 306-322

  Wichmann, Anne B ^a   Adang, Eddy M M ^a   Stalmeier, Peep F M ^a   Kristanti, Sinta ^a   Van Den Block, Lieve ^b   Vernooij Dassen, Myrra J F J ^a   Engels, Yvonne ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Cost effectiveness analysis; Debate; Palliative care; Quality Adjusted Life Year

Indexed keywords

CINAHL; COST EFFECTIVENESS ANALYSIS; EMBASE; EMPIRICISM; HUMAN; MEDICAL SUBJECT HEADINGS; MEDLINE; PALLIATIVE THERAPY; QUALITY ADJUSTED LIFE YEAR; RESOURCE ALLOCATION; SYSTEMATIC REVIEW; THEORETICAL MODEL; COST BENEFIT ANALYSIS; ECONOMICS; STANDARDS;

COST-BENEFIT ANALYSIS; HUMANS; PALLIATIVE CARE; QUALITY-ADJUSTED LIFE YEARS;

EID: 85018185735     PISSN: 02692163     EISSN: 1477030X     Source Type: Journal    
DOI: 10.1177/0269216316689652     Document Type: Review

References (84)

1. World Health Organization (WHO). The right to health. Factsheet no. 31. Geneva: WHO, 2015.
2. National Institutes of Health (NIH). Improving end-of-life care: consensus and state-of-the-science statements. Bethesda, MD: NIH, 2004, pp. 1-28.
3. Hall S, Petkova H, Tsouros A, et al. Palliative care for older people: better practices. Geneva: World Health Organization (WHO), 2011.
4. World Health Organization (WHO). The world health report 2006: working together for health. Geneva: WHO, 2006.
5. Egan TM. QALYs or quackery? The quagmire of quantifying the cost of breathing. J Thorac Cardiovasc Surg 2002; 123: 406-408.
6. Hughes J. Palliative care and the QALY problem. Health Care Anal 2005; 13: 289-301.
7. Round J. Is a QALY still a QALY at the end of life? J Health Econ 2012; 31: 521-527.
8. Yang YT and Mahon MM. Palliative care for the terminally ill in America: the consideration of QALYs, costs, and ethical issues. Med Health Care Philos 2012; 15: 411-416.
9. Dolan P, Lee H, King D, et al. Valuing health directly. BMJ 2009; 339: b2577.
10. National Institute for Health and Clinical Excellence (NICE). Guide to the methods of technology appraisal 2013: process and methods guides. London: NICE, 2013.
11. ZINL. Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg. Zorginstituut Nederland 2015. Available at: https://www.zorginstituutnederland.nl/over-ons/werkwijzen-en-procedures/adviseren-over-en-verduidelijken-van-het-basispakket-aan-zorg/beoordelingvan-geneesmiddelen/richtlijnen-voor-economische-evaluatie. (accessed 26 January 2017).
12. Normand C. Measuring outcomes in palliative care: limitations of QALYs and the road to PalYs. J Pain Symptom Manage 2009; 38: 27-31.
13. McNamee P and Seymour J. Incorporation of process preferences within the QALY framework: a study of alternative methods. Med Decis Making 2008; 28: 443-452.
14. Coast J. Strategies for the economic evaluation of end-of-life care: making a case for the capability approach. Expert Rev Pharmacoecon Outcomes Res 2014; 14: 473-482.
15. Phillips C and Thompson G.What is QALY? Health Econ 2009; 1: 400-405.
16. Sculpher MJ, Pang F, Manca A, et al. Generalisability in economic evaluation studies in healthcare: a review and case studies. Health Technol Assess 2004; 8: iii-iv, 1-192.
17. Murtagh FEM, Groeneveld EI, Kaloki YE, et al. Capturing activity, costs, and outcomes: the challenges to be overcome for successful economic evaluation in palliative care. Progr Palliat Care 2013; 21: 232-235.
18. Normand C. Setting priorities in and for end-of-life care: challenges in the application of economic evaluation. Health Econ Policy Law 2012; 7: 431-439.
19. Kinghorn P and Coast J. Do we have the correct health economics methods to evaluate end of life care? An analysis of stakeholder perspectives. BMJ Support Palliat Care 2014; 4: A4-A5.
20. Whittemore R and Knafl K. The integrative review: updated methodology. J Adv Nurs 2005; 52: 546-553.
21. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 2010; 8: 336-341.
22. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009; 151: 264-269.
23. O'Cathain A, Murphy E and Nicholl J. Three techniques for integrating data in mixed methods studies. BMJ 2010; 341: c4587.
24. Stevenson MD, Macdonald FC, Langley J, et al. The cost-effectiveness of bosentan in the United Kingdom for patients with pulmonary arterial hypertension of WHO functional class III. Value Health 2009; 12: 1100-1105.
25. Ljungman D, Hyltander A and Lundholm K. Cost-utility estimations of palliative care in patients with pancreatic adenocarcinoma: a retrospective analysis. World J Surg 2013; 37: 1883-1891.
26. Furlan JC, Chan KK, Sandoval GA, et al. The combined use of surgery and radiotherapy to treat patients with epidural cord compression due to metastatic disease: a cost-utility analysis. Neuro Oncol 2012; 14: 631-640.
27. Dooms CA, Lievens YN and Vansteenkiste JF. Cost-utility analysis of chemotherapy in symptomatic advanced non small cell lung cancer. Eur Respir J 2006; 27: 895-901.
28. Phippen N, Leath IC, Miller C, et al. Is a home-based palliative care treatment strategy preferable to standard chemotherapy in recurrent cervical cancer? Gynecol Oncol 2013; 131(1): 277-278.
29. Chochinov HM. Death, time and the theory of relativity. J Pain Symptom Manage 2011; 42: 460-463.
30. Yang YT and Mahon MM. Considerations of quality-adjusted life-year in palliative care for the terminally ill. J Palliat Med 2011; 14: 1197.
31. Coast J, Smith RD and Lorgelly P. Welfarism, extra-welfarism and capability: the spread of ideas in health economics. Soc Sci Med 2008; 67: 1190-1198.
32. Coast J, Smith R and Lorgelly P. Should the capability approach be applied in health economics? Health Econ 2008; 17: 667-670.
33. Sen A. Inequality reexamined. New York: Russell Sage Foundation; Oxford: Clarendon Press, 1992.
34. Sen A. Capability and well-being. In:Nussbaum MC and Sen AK (eds) The quality of life. Oxford: Clarendon Press, 1993, pp.30-66.
35. Sen A. The idea of justice. New York: JSTOR, 2009.
36. Nussbaum M. Capabilities as fundamental entitlements: Sen and social justice. Fem Econ 2003; 9: 33-59.
37. Alkire S. Why the capability approach? J Hum Dev 2005; 6: 115-135.
38. Van den Hout WB, van der Linden YM, Steenland E, et al. Single- versus multiple-fraction radiotherapy in patients with painful bone metastases: cost-utility analysis based on a randomized trial. J Natl Cancer Inst 2003; 95: 222-229.
39. Barton MB, Jacob SA and Gebsky V. Utility-adjusted analysis of the cost of palliative radiotherapy for bone metastases. Australas Radiol 2003; 47: 274-278.
40. Pace A, Di Lorenzo C, Capon A, et al. Quality of care and rehospitalization rate in the last stage of disease in brain tumor patients assisted at home: a cost effectiveness study. J Palliat Med 2012; 15: 225-227.
41. Haycox A. Optimizing decision making and resource allocation in palliative care. J Pain Symptom Manage 2009; 38: 45-53.
42. Cowley C. Justifying terminalcare by "retrospective quality-adjusted life-years." J Med Ethics 2010; 36: 290-292.
43. Round J. Death, time, and the theory of relativity: a brief reply? J Pain Symptom Manage 2012; 43: e2-e6.
44. Billingham LJ, Bathers S, Burton A, et al. Patterns, costs and cost-effectiveness of care in a trial of chemotherapy for advanced non-small cell lung cancer. Lung Cancer 2002; 37: 219-225.
45. Arguedas MR, Heudebert GH, Stinnett AA, et al. Biliary stents in malignant obstructive jaundice due to pancreatic carcinoma: a cost-effectiveness analysis. Am J Gastroenterol 2002; 97: 898-904.
46. Neumann PJ, Cohen JT and Weinstein MC. Updating cost-effectiveness - the curious resilience of the $50,000-per-QALY threshold. New Eng J Med 2014; 371: 796-797.
47. Furlan JC, Chan KK, Sandoval GA, et al. The combined use of surgery and radiotherapy to treat patients with epidural cord compression due to metastatic disease: a cost-utility analysis. Neuro Oncol 2012; 14: 631-640.
48. Kahneman D, Diener E and Schwarz N. Well-being: foundations of hedonic psychology. New York: Russell Sage Foundation, 1999.
49. Drummond M, Sculpher M, Torrance G, et al. Methods for the economic evaluation of health care programmes. New York: Oxford University Press, 2005.
50. Howie L and Peppercorn J. Early palliative care in cancer treatment: rationale, evidence and clinical implications. Ther Adv Med Oncol 2013; 5: 318-323.
51. Rowland K, Schumann S-A and Hickner J. Palliative care: earlier is better (Priority Updates to Research Literature (PURLs)) J Fam Pract 2010; 59: 695-698.
52. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. New Eng J Med 2010; 363: 733-742.
53. Claxton K, Martin S, Soares M, et al. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technol Assess 2015; 19: 1-503, v-vi.
54. Brouwer WB, Culyer AJ, van Exel NJA, et al. Welfarism vs. extra-welfarism. J Health Econ 2008; 27: 325-338.
55. Bailey C, Orlando R, Kinghorn P, et al. Measuring the quality of end of life using ICECAP SCM: feasibility and acceptability. BMJ Support Palliat Care 2014; 4: 112.
56. Echteld MA. Meetinstrumenten Palliatieve Zorg. VUmc EMGO-Instituut 2016. Available at: https://www.vumc.nl/afdelingen/meetinstr-palliatieve-zorg/ (accessed 27 January 2017).
57. Huber M, Knottnerus JA, Green L, et al. How should we define health? BMJ 2011; 343: d4163.
58. Groot MM, Derksen EW, Crul BJ, et al. Living on borrowed time: experiences in palliative care. Patient Educ Couns 2007; 65: 381-386.
59. Stalmeier PF, Lamers LM, Busschbach JJ, et al. On the assessment of preferences for health and duration: maximal endurable time and better than dead preferences. Med Care 2007; 45: 835-841.
60. Mehrez A and Gafni A. Quality-adjusted life years, utility theory, and healthy-years equivalents. Med Decis Making 1989; 9: 142-149.
61. Palmer S and Torgerson DJ. Economics notes: definitions of efficiency. BMJ 1999; 318: 1136.
62. Sprangers MA and Schwartz CE. Integrating response shift into health-related quality of life research: a theoretical model. Soc Sci Med 1999; 48: 1507-1515.
63. Norman G. Hi! How are you? Response shift, implicit theories and differing epistemologies. Qual Life Res 2003; 12: 239-249.
64. Kim H, Rajagopalan MS, Beriwal S, et al. Cost-effectiveness analysis of single fraction of stereotactic body radiation therapy compared with single fraction of external beam radiation therapy for palliation of vertebral bone metastases. Int J Radiat Oncol Biol Phys 2015; 91: 556-563.
65. Miller AR, Cantor SB, Peoples GE, et al. Quality of life and cost effectiveness analysis of therapy for locally recurrent rectal cancer. Dis Colon Rectum 2000; 43: 1695-1703.
66. Phippen NT, Leath CA 3rd, Miller CR, et al. Are supportive care-based treatment strategies preferable to standard chemotherapy in recurrent cervical cancer? Gynecol Oncol 2013; 130: 317-322.
67. Shenfine J, McNamee P, Steen N, et al. A randomized controlled clinical trial of palliative therapies for patients with inoperable esophageal cancer. Am J Gastroenterol 2009; 104: 1674-1685.
68. Van den Hout WB, Kramer GW, Noordijk EM, et al. Costutility analysis of short- versus long-course palliative radiotherapy in patients with non-small-cell lung cancer. J Natl Cancer Inst 2006; 98: 1786-1794.
69. Lowery W, Lowery A, Barnett J, et al. Cost effectiveness of early palliative care intervention in recurrent platinum resistant ovarian cancer. Gynecol Oncol 2013; 131(1): 283-284.
70. Chochinov HM. Relatively speaking. J Pain Symptom Manage 2012; 43: e6-7.
71. Coy P, Schaafsma J, Schofield JA. The cost-effectiveness and cost-utility of high-dose palliative radiotherapy for advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2000; 48: 1025-1033.
72. Goldfeld KS, Hamel MB, Mitchell SL. The cost-effectiveness of the decision to hospitalize nursing home residents with advanced dementia. J Pain Symptom Manage 2013; 46: 640-651.
73. Jeurnink SM, Polinder S, Steyerberg EW et al. Cost comparison of gastrojejunostomy versus duodenal stent placement for malignant gastric outlet obstruction. J Gastroenterol 2010; 45: 537-543.
74. Johnson MJ, Kanaan M, Richardson G et al. A randomised controlled trial of three or one breathing technique training sessions for breathlessness in people with malignant lung disease. BMC Med 2015; 13: 213.
75. Konski A. Radiotherapy is a cost-effective palliative treatment for patients with bone metastasis from prostate cancer. Int J Radiat Oncol Biol Phys 2004; 60: 1373-1378.
76. Konski A, James J, Hartsell W et al. Economic analysis of radiation therapy oncology group 97-14: multiple versus single fraction radiation treatment of patients with bone metastases. Am J Clin Oncol 2009; 32: 423-428.
77. Lowery WJ, Lowvery AW, Barnett JC et al. Cost-effectiveness of early palliative care intervention in recurrent platinum-resistant ovarian cancer. Gynecol Oncol 2013; 130: 426-30.
78. Olden AM, Holloway R. Treatment of malignant pleural effusion: PleuRx catheter or talc pleurodesis? A cost-effectiveness analysis. J Palliat Med 2010; 13: 59-65.
79. Roberts KJ, Sutton AJ, Prasad KR et al. Cost-utility analysis of operative versus non-operative treatment for colorectal liver metastases. Br J Surg 2015; 102: 388-398.
80. Roth JA, Carlson JJ. Cost-effectiveness of gemcitabine + cisplatin vs. gemcitabine monotherapy in advanced biliary tract cancer. J Gastrointest Cancer 2012; 43: 215-223.
81. Sahlen KG, Boman K, Bränström M. A cost-effectiveness study of person-centered integrated heart failure and palliative home care: Based on a randomized controlled trial. Palliat Med 2016; 30: 296-302.
82. Shafiq M, Frick KD, Lee H et al. Management of Malignant Pleural Effusion: A Cost-Utility Analysis. J Bronchology Interv Pulmonol 2015; 22: 215-225.
83. Teerawattananon Y, Mugford M, Tangcharoensathien V. Economic evaluation of palliative management versus peritoneal dialysis and hemodialysis for end-stage renal disease: evidence for coverage decisions in Thailand. Value Health 2007; 10: 61-72.
84. Xinopoulos D, Dimitroulopoulos D, Moschandrea I et al. Natural course of inoperable esophageal cancer treated with metallic expandable stents: quality of life and cost-effectiveness analysis. J Gastroenterol Hepatol 2004; 19: 1397-1402.